Insomnia: A Nutritional and Natural-Health Reference
1. Definition and Clinical Presentation
Insomnia is defined as the symptom of difficulty falling asleep, repeated awakenings with difficulty returning to sleep, or sleep that is nonrestorative or poor in quality, often accompanied by the perception of short overall sleep duration. In diagnostic terms, insomnia encompasses difficulties of initiating and maintaining sleep, early awakening, and poor subjective sleep quality despite adequate opportunity and circumstances for sleep, with impairment of daytime performance.
In contrast to situational and transient insomnias defined as insomnia symptoms attributed to a certain event or occurring transiently (less than 3 months), chronic insomnias require specific attention due to their impact on sleep quality, daytime performance, and quality of life. According to ICD-10, a clinically significant insomnia disorder is present when symptoms persist for 4 weeks; according to DSM-5, a duration of 3 months is required for the designation of chronic insomnia.
Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. The prevalence of insomnia disorder is approximately 10% to 20%, with approximately 50% having a chronic course. Insomnia is a risk factor for impaired function, development of other medical and mental disorders, and increased health care costs.
Daytime consequences are a defining feature of the diagnosis. Daytime sequelae include altered mood, impaired functionality, increased absenteeism, and an increased risk for depression. Insomnia often leads to fatigue, energy depletion, impairment in concentration, and increased irritability.
2. Body Systems Involved
2.1 Neurobiological Architecture of Sleep
The suprachiasmatic nucleus (SCN) acts as the body's master biological clock, regulating the sleep-wake cycle and coordinating it with external light-dark cycles, responding to light information from the environment to synchronize physiological processes with the 24-hour day-night cycle. Other brain regions, including the hypothalamus and limbic system, play significant roles in sleep regulation. The hypothalamus is involved in the regulation of various physiological processes, including sleep and arousal, while the limbic system, which is crucial for emotional processing, can influence sleep quality, with emotional dysregulation often contributing to insomnia.
The sleep-promoting system involves neurotransmitters such as gamma-aminobutyric acid (GABA) and galanin, while the wake-promoting system involves neurotransmitters like dopamine, norepinephrine, and serotonin. GABA is the primary inhibitory neurotransmitter in the brain and is involved in promoting sleep; serotonin is involved in regulating the sleep-wake cycle, with its activity typically decreasing during sleep. Melatonin, a hormone produced by the pineal gland, promotes sleepiness and is regulated by the suprachiasmatic nucleus.
Current neurobiological models propose that insomnia results from persistent activity in wake-promoting neural structures during NREM sleep. The etiology and pathophysiology of insomnia involve genetic, environmental, behavioral, and physiological factors culminating in hyperarousal.
2.2 Neuroendocrine and Autonomic Systems
Comorbid insomnia can originate from neurodegenerative, inflammatory, traumatic, or ischemic changes in sleep-regulating brainstem and hypothalamic nuclei with consecutive changes of neurotransmitters. Stress-related hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis, with elevated cortisol levels, is a recognized contributor to the hyperarousal state characteristic of chronic insomnia.
2.3 Cardiovascular System
Insomnia has been closely associated with cardiovascular disease, including myocardial infarction. A pooled meta-analysis found a significant association between insomnia and the incidence of myocardial infarction compared with non-insomniacs (relative risk = 1.69, 95% CI = 1.41–2.02), with the highest association detected between sleep duration of five hours or fewer and myocardial infarction incidence compared to seven to eight hours of sleep (RR = 1.56, 95% CI = 1.41–1.73).
2.4 Neurodegeneration
Insomnia is a common symptom of many neurodegenerative diseases, and more recently it has been identified as a risk factor for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. A large-scale meta-analysis including 16 studies with a combined sample size of over 9 million individuals concluded that insomnia is linked to the risk of dementia, Alzheimer's disease, and vascular dementia. The authors noted that these results should be interpreted with caution due to remaining heterogeneity across included studies.
3. Contributing and Associated Factors
3.1 Psychological and Behavioral Factors
Five variables have been consistently associated with new onset of insomnia syndrome in population-based research: previous episode of insomnia, positive family history of insomnia, higher arousability predisposition, poorer self-rated general health, and higher bodily pain.
Factors related to insomnia can be classified into: patient demographic characteristics (e.g., age, marital or socioeconomic status); mental state (e.g., depression or anxiety); physical state (e.g., fatigue, pain, or restless legs syndrome); and treatment-related factors. Comorbidities such as pain, depression, and anxiety, and certain pharmaceuticals, may cause insomnia and/or other sleep problems.
3.2 Circadian and Environmental Factors
The components most often considered part of sleep hygiene research literature include the behavioral components of caffeine intake, alcohol consumption, exercise/physical activity, sleep timing/regularity, napping, smoking, wind-down routine, stimulus control, food intake, sleep restriction, and sleep medication use; the environmental components of light, noise, temperature, comfortable bedding, and bedpartner; and stress and other psychological factors that influence sleep.
3.3 Medical Comorbidities
Significant risk factors for insomnia include female sex, anxiety, depression, longer disease duration, diabetes, and gastritis. Potential contributors to the diabetes–insomnia association include sleep disruption from nocturia, neuropathic pain, glycemic fluctuations, and psychological distress.
4. Nutrients Studied in Relation to Insomnia
4.1 Melatonin
Traditional context: Melatonin is an endogenous hormone rather than a traditional herbal remedy; its supplemental use emerged following the identification of its role in circadian regulation in the latter decades of the twentieth century.
Scientific evidence: A 2013 meta-analysis of 19 randomized placebo-controlled trials involving 1,863 participants with primary sleep disorders found evidence of small but statistically significant improvements in sleep onset latency (reduction of 7.06 minutes), total sleep time (increased by 8.25 minutes), and overall sleep quality with melatonin use. These effects do not appear to dissipate with continued melatonin use. The investigators concluded that although the absolute benefit of melatonin compared to placebo is smaller than other pharmacologic treatments, melatonin may have a role in the treatment of insomnia given its relatively benign side-effect profile.
Current evidence suggests that melatonin may be useful in treating several sleep disorders, including jet lag, delayed sleep phase disorder, and sleep problems related to shift work. A 2016 review of two studies (n=52) showed that melatonin supplements reduced the time it took for people with delayed sleep-wake phase disorder to fall asleep when compared to placebo, by approximately 22 minutes on average. Evidence strength for primary insomnia disorder per se is characterized as modest by the NCCIH.
4.2 Magnesium
Traditional context: Magnesium has been used in traditional folk and naturopathic medicine as a muscle-relaxing and nerve-calming mineral, often recommended in the context of stress and restlessness.
Scientific evidence: Observational research associates greater magnesium consumption with better sleep quality, including shorter sleep onset latency, longer sleep duration, and reduced daytime sleepiness. Clinical trials further suggest that magnesium supplementation enhances sleep efficiency and reduces insomnia severity, potentially through mechanisms such as increased melatonin production and reduced cortisol levels. A recent systematic review found an association between magnesium status and sleep quality in observational studies, but highlighted inconsistencies in interventional trials: two RCTs showed improvements in sleep efficiency, time, or latency, while three found no significant effects — and these trials included only 247 participants in total.
A pooled meta-analysis showed that post-intervention sleep onset latency was 17.36 minutes less after magnesium supplementation compared to placebo (95% CI −27.27 to −7.44, p=0.0006), while the improvement in total sleep time of 16.06 minutes was statistically insignificant. Overall, the evidence base is limited by small trial numbers and heterogeneous populations; magnesium supplementation is often purported to improve sleep; however, as both an over-the-counter sleep aid and a complementary medicine, there is limited evidence to support this assertion.
4.3 L-Tryptophan
Traditional context: Tryptophan is an essential amino acid that the body cannot synthesize and must be supplied through food; dietary sources include chicken, turkey, eggs, milk, fish, cheese, beans, and pumpkin seeds. Its use as a sleep-promoting supplement has roots in mid-twentieth-century nutritional psychiatry.
Scientific evidence: Tryptophan is a precursor of melatonin and serotonin and can cross the blood-brain barrier. A 2021 systematic review and meta-analysis of 10 RCTs (n=258 participants) concluded that daily L-tryptophan doses of 1 g or more improved subjective sleep quality metrics, including reduced wake-after-sleep onset, with a standardized mean difference of −0.56 versus placebo (P<0.05), while effects were negligible at doses below 1 g. Results have been mixed or negative in entirely normal subjects, severe insomniacs, and people with serious medical or psychiatric illness. Limitations of the sleep literature for L-tryptophan include small sample sizes (median n=20 per arm), short durations (1–4 weeks), and potential publication bias, and long-term data beyond 3 months are sparse. The American Academy of Sleep Medicine (updated 2017) does not endorse L-tryptophan as first-line therapy for insomnia, prioritizing cognitive behavioral therapy.
Clinical and experimental studies have shown that increasing dietary tryptophan intake can reduce the time it takes to fall asleep, and tryptophan's effects appear to be dose-dependent and more pronounced when consumed in combination with carbohydrates, which facilitate its transport into the brain. Diets high in high-glycemic index carbohydrates — particularly when consumed about four hours before bedtime — have also been shown to shorten the time to fall asleep, possibly by enhancing tryptophan availability in the brain.
4.4 5-Hydroxytryptophan (5-HTP)
Traditional context: 5-HTP is a naturally occurring intermediary metabolite in the tryptophan-to-serotonin pathway and is produced commercially from the seeds of Griffonia simplicifolia. It has been used in European and North American nutritional medicine since the 1980s.
Scientific evidence: One 12-week randomized controlled trial showed that 5-HTP supplementation had an overall favorable effect on certain sleep quality components and increased serum serotonin concentration. Evidence for 5-HTP as a sleep aid is limited and based on small, older studies; in healthy adults, two very small preliminary studies in the 1970s suggested certain sleep benefits. The overall evidence base remains insufficient to draw firm clinical conclusions about dose, formulation, and long-term efficacy.
4.5 Vitamin D
Scientific evidence: Vitamin D deficiency is associated with a higher risk of insomnia, including short sleep duration, poor quality of sleep, and daytime sleepiness; studies suggest a correlation between deterioration in sleep quality and a deficiency of 25-hydroxyvitamin D in serum. Vitamin D deficiency has been linked to shorter sleep duration and poorer sleep quality, likely due to its influence on circadian rhythms. Intervention data are still emerging, and the evidence linking supplementation directly to improved insomnia outcomes remains preliminary.
4.6 Omega-3 Fatty Acids and Antioxidants
Scientific evidence: A systematic review and meta-analysis found that tryptophan, vitamin D, omega-3 fatty acids, zinc, and antioxidants may enhance sleep quality by decreasing sleep latency and wake after sleep onset, increasing sleep efficiency, and extending total sleep time. However, heterogeneity in data reporting limits conclusive comparisons across supplement subtypes, as insufficient data were available for certain categories.
5. Herbs and Botanical Ingredients
5.1 Valerian (Valeriana officinalis)
Traditional use: Valerian root has been used as a sedative herb in European folk medicine for centuries, and its roots and rhizomes were described in ancient Greek and Roman texts for their calming properties. It was a prominent remedy in nineteenth-century botanical medicine across Europe and North America.
Scientific evidence: The evidence on whether valerian is helpful for sleep problems is inconsistent. In its 2017 clinical practice guidelines, the American Academy of Sleep Medicine recommended against using valerian for chronic insomnia in adults. Some findings suggest that valerian could be effective in improving sleep quality and reducing insomnia symptoms through modulation of neurotransmitter systems, but the evidence base is mixed. Valerian is probably the species that has been studied most for its effects on different types of nervous alterations, especially insomnia and anxiety. Evidence strength is characterized by regulatory and clinical bodies as insufficient for definitive recommendations.
5.2 Ashwagandha (Withania somnifera)
Traditional use: Ashwagandha root powder and extracts have long been used in Ayurvedic medicine to improve sleep and anxiety. It is classified as a rasayana (rejuvenating tonic) in classical Ayurveda and has been used for millennia on the Indian subcontinent, typically prepared as a root decoction or powder in warm milk.
Scientific evidence: A systematic review and meta-analysis of five RCTs found that ashwagandha extract exhibited a small but significant effect on overall sleep (standardized mean difference −0.59; 95% CI −0.75 to −0.42), with effects on sleep more prominent in the subgroup of adults diagnosed with insomnia. The five trials contained a total of 400 participants. A double-blind, placebo-controlled trial in 60 insomnia patients found that sleep onset latency was significantly shorter (p=0.019) after 10 weeks with ashwagandha root extract compared to placebo. All five trials included in the meta-analysis were conducted in India, which represents a limitation in terms of generalizability. Evidence is promising but limited by small sample sizes and geographic concentration of trials.
5.3 Passionflower (Passiflora incarnata)
Traditional use: Passionflower has been cited in folk medicinal practices for sleep disorders. It has been used as a sedative and anxiolytic herb in North American and European herbal traditions for several centuries, typically prepared as an infusion or tincture.
Scientific evidence: Passionflower has preclinical investigations showing interaction with the GABA system in addition to human clinical trials. A scoping review of over-the-counter products found that passionflower, either alone or in combination with valerian and hops, was among the products showing significant benefits on sleep outcomes. Extracts from passionflower have been investigated for sleep disturbances, but so far the amount of data is not sufficient to definitively evaluate their effect on insomnia disorders. Overall, evidence is preliminary and restricted to small clinical trials.
5.4 Chamomile (Matricaria chamomilla)
Traditional use: Chamomile has been used as a calming evening infusion throughout Europe and the Mediterranean for centuries, employed in traditional Galenic medicine for its mild sedative and antispasmodic properties.
Scientific evidence: A recently published systematic review and meta-analysis indicated chamomile as efficacious and safe for improving sleep quality and generalized anxiety disorders, but highlighted a scarce effect for insomnia per se. Sparse or no scientific data were found to support the efficacy of chamomile as a hypnotic. A study of sixty elderly people who took chamomile extract capsules (200 mg) twice a day for 28 consecutive days did report improvements in general sleep quality and sleep latency as measured by the Pittsburgh Sleep Quality Index. Evidence remains limited and study quality is variable.
5.5 Lemon Balm (Melissa officinalis)
Traditional use: Lemon balm has been used in European herbal medicine since at least the medieval period, often combined with valerian, and was described by physicians such as Paracelsus and in the herbal traditions of the German-speaking world as a calming nervine.
Scientific evidence: A double-blinded clinical study reported the anxiolytic effect of lemon balm on patients after cardiac surgery, improving their sleep quality. Accumulating evidence highlights that lemon balm, among other selected medicinal plants, may exert relevant hypnotic or anxiolytic effects, thus complementing melatonergic strategies in the management of insomnia. Data for lemon balm in sleep disturbances are as yet insufficient to draw firm conclusions about efficacy as a standalone agent.
5.6 Hops (Humulus lupulus)
Traditional use: Hops have been used in traditional European phytomedicine as a mild sedative, often in combination with valerian. In medieval Europe, hop pillows were placed near the head to promote sleep, and hop preparations were described in nineteenth-century German pharmacy texts.
Scientific evidence: A double-blind, randomized placebo-controlled trial on 171 volunteers with sleep difficulties reported no significant changes in sleep quality after taking 500 mg hops for 2 weeks. Another study with 101 volunteers with chronic primary insomnia taking 50 mg hop extract per day for a month showed no effects on sleep quality, melatonin metabolism, or sleep-wake cycle. Some clinical trials have shown hops in combination formulas to show promise, but evidence for hops alone remains weak.
5.7 Kava (Piper methysticum)
Traditional use: Kava has been used for centuries in Pacific Islander cultures as a ceremonial and social beverage with anxiolytic and sedative properties, prepared as an aqueous extract of the root.
Scientific evidence: Kava has been well studied and has shown good results in reducing anxiety and hypnotic effects. Although kava is said to have sedative properties, very little research has been conducted on whether this herb is helpful specifically for insomnia. More importantly, the use of kava has been linked to liver injury that is sometimes serious or even fatal, and the exact cause and frequency of the liver damage are unclear. Regulatory agencies in several jurisdictions have restricted or banned the sale of kava supplements.
5.8 Lavender (Lavandula angustifolia)
Traditional use: Lavender has been used in European and Mediterranean folk medicine as an aromatic sedative, both topically (lavender sachets, pillows) and as an infused tea, for centuries.
Scientific evidence: An oral preparation of lavender essential oil (Silexan) has been studied in clinical trials for anxiety-associated sleep disturbance. Accumulating evidence highlights that lavender may exert relevant hypnotic or anxiolytic effects. Several RCTs of lavender products have been included in scoping reviews of over-the-counter insomnia products, with some individual trials reporting significant effects on sleep outcomes. Evidence for inhaled lavender aromatherapy alone is limited and largely derived from small observational studies.
6. Dietary Patterns and Food-Based Factors
6.1 Mediterranean Dietary Pattern
A systematic review comprised 23 reports describing the relationship between adherence to the Mediterranean diet and different sleep features, including sleep quality, sleep duration, daytime sleepiness, and insomnia symptoms. The majority of included studies reported a significant association between higher adherence to the Mediterranean diet and a lower likelihood of having poor sleep quality, inadequate sleep duration, excessive daytime sleepiness, or symptoms of insomnia. Overall, most studies showed that higher adherence to a Mediterranean dietary pattern was associated with better sleep features, and findings are in line with those from randomized clinical trials, suggesting that dietary intervention with a Mediterranean diet may improve sleep features.
Certain key foods that are part of the Mediterranean diet are rich in melatonin, serotonin, and vitamin D, and these foods may enhance sleep. However, most studies had a cross-sectional design, limiting causal inference.
6.2 Specific Foods Studied
Studies have linked consumption of fatty fish, dairy, kiwi fruit, tart cherries, and other berries such as strawberries and blueberries with better sleep. One of the common pathways through which these foods may affect sleep is by providing melatonin, an important modulator of sleep and wake cycles. Functional foods such as tart cherry juice and kiwifruit demonstrate potential benefits for sleep quality, though the evidence base for each food individually remains relatively small.
A systematic review indicated healthier foods are associated with improved sleep quality, whereas highly processed and sugary foods are associated with poorer sleep quality.
6.3 Chrononutrition: Meal Timing and Sleep
Emerging research into chrononutrition — the study of how the timing, frequency, and composition of food intake interact with the body's circadian system — highlights that when we eat may be just as important as what we eat, with irregular meal timing potentially disrupting circadian alignment and impairing sleep.
7. Dietary and Lifestyle Factors with Established Evidence
7.1 Caffeine
By blocking the adenosine neuromodulator and receptor system, which contributes importantly to sleep-wake regulation, caffeine impairs nighttime sleep, at least in vulnerable individuals. A systematic review and meta-analysis quantified that caffeine consumption reduced total sleep time by 45 minutes and sleep efficiency by 7%, with an increase in sleep onset latency of 9 minutes and wake after sleep onset of 12 minutes. Even doses ingested up to 6 hours before bedtime were associated with disturbances in both subjectively and objectively assessed sleep. The effect of regular caffeine consumption on perceived sleep quality is still unclear due to conflicting findings; some evidence suggests caffeine reduces total sleep time, while other findings indicate no significant effect, with variations in study designs and caffeine measurement methods complicating conclusions.
7.2 Alcohol
Caffeine, alcohol, heavy meals, and light exposure later in the day are associated with fragmented poor-quality sleep. Although alcohol may transiently reduce sleep onset latency, the evidence in the research literature consistently associates alcohol consumption before sleep with disrupted sleep architecture, particularly suppression of REM sleep and increased nighttime awakenings. Smoking, alcohol consumption, excessive stress, and excessive caffeine intake in the diet are factors that influence the deterioration of sleep quality; alcohol is not recommended before going to sleep in order to ensure good sleep hygiene.
7.3 Physical Activity and Exercise
Recommendations to improve sleep include achieving 7 to 9 hours of sleep, maintaining a consistent sleep-wake schedule, a regular bedtime routine, engaging in regular exercise, and adopting a contemplative practice. The research literature on sleep hygiene identifies physical activity as a behavioral component with meaningful impact on sleep timing and quality, though the evidence for optimal timing and type of exercise remains an active research area.
7.4 Relaxation Practices
There is evidence to suggest that using relaxation techniques, such as progressive relaxation, guided imagery, biofeedback, or deep breathing exercises, before bedtime can be helpful components of a successful strategy to improve sleep habits. The available evidence on efficacy of relaxation techniques for sleep disorders consists of several small randomized controlled trials, systematic reviews, meta-analyses, and specific recommendations in independent clinical practice guidelines.
7.5 GABA-Modulating Phytomedicines: General Evidence Overview
Ten phytomedicines have been identified as having preclinical investigations showing interaction with the GABA system in addition to human clinical trials: kava, valerian, pennywort, hops, chamomile, Ginkgo biloba, passionflower, ashwagandha, skullcap, and lemon balm. It is important to note that preclinical GABA-modulating activity does not automatically translate to clinically meaningful hypnotic effects in humans, and evidence strength varies considerably across this group.
7.6 Overall Nutritional Status
Proper nutrition that is rich in tryptophan, vitamin D, and gamma-aminobutyric acid can improve the quality of sleep; by consuming foods rich in these substances, sleep effectiveness and actual sleep time are improved. Substances such as alcohol, nicotine, excess caffeine, and cannabis negatively affect the quality of sleep.
There is a recognized need for systematic research into the evidence behind each individual sleep hygiene factor, particularly those currently lacking robust evidence, such as the influence of diet and nutrition. Much of the current evidence is observational and cross-sectional; causal inference must therefore be made with caution.
References
Go back